Press release
Investigation announced for Investors in Humanigen, Inc. (NASDAQ: HGEN) over possible Violations of Securities Laws
An investigation for investors in Humanigen, Inc. (NASDAQ: HGEN) shares over potential securities laws violations by Humanigen.
Investors who purchased shares of Humanigen, Inc. (NASDAQ: HGEN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Humanigen, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Short Hills, NJ based Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. On July 13, 2022, Humanigen, Inc. disclosed that its trial of lenzilumab did not attain statistical significance on the primary endpoint of the proportion of subjects with baseline CRP
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Humanigen, Inc. (NASDAQ: HGEN) over possible Violations of Securities Laws here
News-ID: 2703893 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Humanigen
Acute Graft-versus-Host Disease Market: Share & Size, Forecasts a CAGR of 4.10% …
According to a new report published by CoherentMI The Global Acute Graft-versus-Host Disease Market is estimated to be valued at USD 3.9 Bn in 2024 and is expected to reach USD 5.9 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.10% from 2024 to 2031.
Most recent Report, named "Acute Graft-versus-Host Disease Market" Patterns, Offer, Size, Development, Opportunity and Forecast 2024-2031, by CoherentMI offers a…
Investigation for Long-Term Investors in shares of Humanigen, Inc. (NASDAQ: HGEN …
An investigation was announced for long-term investors in shares of Humanigen, Inc. (NASDAQ: HGEN) concerning potential breaches of fiduciary duties by certain directors of Humanigen, Inc.
Investors who are current long term investors in Humanigen, Inc. (NASDAQ: HGEN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: HGEN stocks follows…
Deadline coming up on Oct. 25th in Lawsuit for Investors in shares of Humanigen, …
A deadline is coming up on October 25, 2022 in the lawsuit filed for certain investors of Humanigen, Inc. (NASDAQ: HGEN) over alleged securities laws violations by Humanigen, Inc.
Investors who purchased shares of Humanigen, Inc. (NASDAQ: HGEN) have certain options and there are strict and short deadlines running. Deadline: October 25, 2022. NASDAQ: HGEN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Lawsuit filed for Investors in shares of Humanigen, Inc. (NASDAQ: HGEN) over all …
An investor, who purchased shares of Humanigen, Inc. (NASDAQ: HGEN), filed a lawsuit over alleged violations of Federal Securities Laws by Humanigen, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Humanigen, Inc. (NASDAQ: HGEN) have certain options and for certain investors are short and strict deadlines running. Deadline: October 25, 2022. NASDAQ: HGEN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Investigation announced for Investors in Humanigen, Inc. (NASDAQ: HGEN) over pot …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Humanigen, Inc.
Investors who purchased shares of Humanigen, Inc. (NASDAQ: HGEN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Humanigen, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Burlingame, CA based Humanigen,…
Investigation announced for Investors in shares of Humanigen, Inc. (NASDAQ: HGEN …
An investigation was announced concerning potential securities laws violations by Humanigen, Inc. in connection with certain financial statements.
Investors who purchased shares of Humanigen, Inc. (NASDAQ: HGEN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) concerning whether a series of statements…
